Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
University of Illinois researchers led by Zan Luthey‑Schulten have built a three‑dimensional kinetic model of the minimal bacterium JCVI‑syn3A that simulates an entire 105‑minute cell cycle. By assigning DNA replication to a dedicated GPU and running other cellular dynamics on a second GPU, each simulation completed in six days—a task that previously demanded years of compute time. The model tracks every gene, protein, RNA and metabolic reaction, reproducing replication, growth and division timing with an average error of two minutes versus laboratory measurements. The work appears in Cell and opens a new platform for virtual cellular biology.
Stable GLP‑1 receptor agonists such as Exendin‑4 and Ozempic improve beta‑cell viability by modulating gene expression. Researchers at the Salk Institute discovered that these drugs induce phosphorylation of Med14, a core subunit of the Mediator transcription complex. Phosphorylated Med14 enables...
Regeneron’s Chinese partner Hansoh announced that its dual GLP‑1/GIPR agonist olatorepatide achieved a 19% mean weight loss in a Phase 3 trial of 604 obese or overweight adults, meeting both co‑primary endpoints. The study reported lower gastrointestinal adverse events compared with...
Bristol Myers Squibb announced that its oral CELMoD candidate mezigdomide met primary endpoints in the Phase 3 SUCCESSOR‑2 trial for relapsed or refractory multiple myeloma. The open‑label study showed a statistically significant improvement in progression‑free survival compared with the current standard...
Medidata, a Dassault Systèmes brand, has partnered with eSource specialist CRIO to automate clinical data flow from site systems into the Medidata Platform. The plug‑and‑play integration now serves over 2,500 research sites in roughly 30 countries, delivering near‑100% data accuracy and...
The new Huberman Lab episode is out: Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson 0:00 Alex Marson 2:21 Diseases & Current Biological Landscape; AI & Computational Tools 5:56 Immune System, Innate vs Adaptive Immune System 10:55 Thymus, T...
Carbios, once a flagship of France’s industrial biotech, has seen its enzymatic PET recycling ambitions hampered by financing gaps, a delayed Longlaville plant and a costly reorganisation. The company’s cash fell to €72 million by mid‑2025, prompting a 40 % cut in...
Researchers reported in Nature Communications that early pregnancy prevents the accumulation of a novel hybrid mammary cell type in mice. These cells, which produce the inflammatory cytokine IL33, increase with age in never‑pregnant females and are linked to tissue changes...
Pulse Biosciences reported long‑term results from its first‑in‑human nPulse Vybrance study, showing an average 74% reduction in benign thyroid nodule volume after 15‑22 months. The data, presented at the 2026 North American Society for Interventional Thyroidology meeting, revealed no nodule...
Bristol Myers Squibb reported positive interim Phase 3 results from the SUCCESSOR‑2 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) significantly extended progression‑free survival versus carfilzomib‑dexamethasone alone in relapsed or refractory multiple myeloma. The trial marks the first...
The Canadian Genomics Strategy Secretariat, Global Affairs Canada and Genome Canada are organizing a genomics trade mission to Boston during the first week of June 2026, coinciding with the Festival of Genomics, Biodata and Artificial Intelligence. Selected Canadian genomics firms...
Tim Harris, a veteran biotech investor, revisits his skepticism about artificial intelligence in drug discovery, noting the surge of AI‑focused startups and sizable funding rounds. He outlines how AI is being applied to molecular dynamics, protein‑protein interaction prediction, and antibody...
Shalabh Gupta, CEO of Unicycive Therapeutics, argues that biotech can benefit from tech‑driven design thinking, rapid prototyping, and disciplined capital allocation. He highlights how the company repurposed automotive battery‑shrinkage technology to create Oxylanthanum carbonate, a kidney‑disease candidate now under FDA...
Not just replication, but triplication of the benefit of revving up cancer immunotherapy with FMT (Yes💩) https://t.co/rXyQdO74FJ
Xenon Pharmaceuticals reported that its Phase 3 X‑TOLE2 trial of azetukalner, a novel Kv7 potassium channel opener, achieved a 53.2% reduction in focal onset seizures at the 25 mg dose, far exceeding expectations and representing the highest placebo‑adjusted efficacy recorded in a...
Chinese hamster ovary (CHO) cells remain the backbone of biopharmaceutical manufacturing, but traditional gene‑editing tools struggle with low knock‑in efficiency. Transposase‑based platforms such as Leap‑In and piggyBac now provide high‑efficiency, multi‑copy integration and can handle large DNA cargos up to...
Two terrific #FDA related pieces by @lizzylawrence.bsky.social & @matthewherper.bsky.social. Matt's is a look at lessons to be drawn from Vinay Prasad's chaotic tenure; Lizzy's delves into the FDA's turning away from adcomms. https://t.co/gC5GNTiPm1 & https://t.co/ygvylHi0uz
Researchers identified a simple protein tail in hornworts, termed RbcS‑STAR, that causes Rubisco enzymes to cluster together, enhancing carbon‑concentrating potential. The STAR region was successfully transferred to Arabidopsis, demonstrating functional clumping in an unrelated model plant. This discovery offers a...
The Chemical Probes Portal’s >30‑fold selectivity rule, originally based on cell‑free assays, is challenged by a new open‑access J. Med. Chem. study comparing DiscoverX kinase panels with NanoBRET cellular profiling. Researchers found that most inhibitors appear less potent in living...
The U.S. government has approved HB4, a genetically engineered wheat tolerant to the herbicide glufosinate, marking the first commercial GMO wheat in America. Glufosinate is linked to reproductive toxicity and is banned in the EU, raising concerns about residue buildup...
. @matthewherper is so damn reasonable. Smart, too. 5 lessons from Vinay Prasad’s turbulent tenure at the FDA https://t.co/R65vPj5ep5
Tacit Therapeutics, an RNA‑editing startup focused on neurological disorders, announced its launch backed by a $19 million financing round. The capital, led by Andreessen Horowitz and DCVC, will fund the development of ADAR‑based therapeutics targeting diseases such as ALS, Huntington’s, and...
The module on target validation walks through how phenotypic and target‑based strategies intersect in immune‑focused drug discovery. It highlights recent literature on TYK2 pseudokinase stabilization as a mechanism to block T‑cell signaling, and cites Icotrokinra and Deucravacitinib as successful examples....
The #VRBPAC committee is scheduled to meet Thursday to advise #FDA on #flu vaccine strain selection. VRBPAC is supposed to have at least 15 members. It currently has 7 voting members & no chair. It has met only twice since...
The FDA’s Oncologic Drugs Advisory Committee will convene on April 30 to evaluate AstraZeneca’s oral SERD camizestrant for first‑line HR‑positive, HER2‑negative breast cancer and its AKT inhibitor Truqap for metastatic hormone‑sensitive prostate cancer. Camizestrant’s Phase 3 SERENA‑6 trial reported a 56% reduction...
We will solve aging or will die trying. Check out the TopTown SuperDNA project. It is no longer a concept - projected launch in Q3 2028. Fully-integrated residential-biotechnology-clinical infrastructure is key to longitudinal AI-powered drug discovery. https://t.co/LK5XaTci29
The FDA rejected Incyte’s supplemental application to add non‑small cell lung cancer to Zynyz’s label, citing compliance failures at Novo Nordisk’s Catalent‑owned Indiana manufacturing plant. The agency’s complete response letter pinpointed inspection findings at the site as the sole approvability...
Amgen’s Lumakras earned accelerated FDA approval in 2021 as the first KRAS‑targeted therapy, but sales have been modest, reaching $92 million in Q4 2025 with only an 8% year‑over‑year increase. A second G12C inhibitor, Krazati, entered the market in 2022, narrowing Amgen’s...
The $RLMD bladder cancer data (phase 2) reported this morning look very good. Another competitive blow to $IBRX particularly at its bloated valuation. https://t.co/wYThfwIpG8
9March: What a roller-coaster ride with $QURE and @US_FDA ! I sum up a wild week--plus $MRNA's could've-been-worse settlement with $ABUS & $ROIV (w/ insights from CEO Matt Gline) and updates from $DAWN and $TNGX in my latest StockWatch for...
Roche’s oral SERD giredestrant failed to meet its primary endpoint in the phase 3 persevERA trial, showing no significant improvement over letrozole when combined with palbociclib in first‑line HR‑positive, HER2‑negative advanced breast cancer. The company now limits U.S. filing to ESR1‑mutated...
Researchers have engineered an iron‑doped mesoporous silica nanoplatform (FOBA) that, when exposed to 808 nm near‑infrared light, uses the Y6 photothermal converter to heat and trigger a PEG gate, creating a transient solvent that enables in‑situ synthesis of the cytotoxic agent...
Researchers have integrated an electric field into electrohydrodynamic (EHD) bioprinting to orient fibrin‑alginate hydrogels, producing nanofiber alignment that directs myocyte organization. The conductive polymer‑enhanced constructs exhibit improved myotube differentiation and mimic native muscle conductivity. In vivo tests on rats demonstrated...
Researchers have engineered a recyclable magnetic nanosystem (Fe3O4/CeO2@BP) that integrates black phosphorus with iron oxide and cerium oxide to achieve rapid, ROS‑driven antibacterial activity in blood. The material can be magnetically retrieved, enabling repeated use across at least 20 disinfection...
Researchers identified macrophage‑derived Semaphorin 7A (SEMA7A) as a potent driver of atherosclerosis. Gene‑expression analysis showed high SEMA7A and its receptor integrin β1 in human mononuclear cells, and mouse models with macrophage‑specific Sema7a deletion exhibited a 57.2% reduction in lesion size and improved...
LifeVac has secured FDA De Novo classification, designating its suction anti‑choking device as a Class II medical device for second‑line treatment after failed basic life support protocols. The clearance confirms the device as a single‑use, non‑powered, non‑invasive tool suitable for adults and...
Aisa Pharma announced positive Phase II data for AISA‑021, a once‑daily calcium channel blocker, in systemic sclerosis‑associated Raynaud’s phenomenon (SSc RP). The double‑blind, placebo‑controlled RECONNOITER trial enrolled 64 patients and showed a 22.1% reduction in weekly Raynaud attacks and a 155% placebo‑adjusted...
Researchers at Washington University have created a blood‑test model using plasma p‑tau217 that can predict the onset of Alzheimer’s symptoms within three to four years. The model, validated on 603 participants, shows age‑dependent timelines, with younger individuals experiencing longer asymptomatic...
The FDA initially refused to review Moderna’s mRNA‑based flu vaccine, prompting surprise among industry observers. After a White House meeting, the agency reversed course and granted Moderna a Type A meeting, effectively resetting the review process. Lanton notes this regulatory flip‑flop...
Health care stakeholders in New York are mobilizing as the state budget negotiations intensify, with the Associated Medical Schools of New York lobbying for an additional $100 million to bolster biomedical research and life‑science jobs. The state already receives over $3.5 billion...
Daiichi Sankyo and AstraZeneca have received FDA priority review for ENHERTU® as a post‑neoadjuvant therapy in HER2‑positive early breast cancer. The decision follows the DESTINY‑Breast05 phase 3 trial, which showed a 53% reduction in invasive disease‑free survival events versus trastuzumab‑emtansine (T‑DM1). Three‑year...
Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik worldwide after an interim safety analysis in the phase 1b/3 SYMPHONY‑1 trial linked the drug to secondary hematologic malignancies. The pull‑back includes terminating all ongoing Tazverik studies and recalling the product in markets...
#GSK to get $300m upfront and $100m upon US FDA approval plus $20m for EU approval and up to $270m sales based payments from Alfasigma who will acquire rights to Linerixibat, a bile acid transporter inhibitor, currently under development.
Process Performance Qualification (PPQ) is the final validation step before commercial manufacturing of cell and gene therapies, but its complexity often triggers delays and compliance risks. The article highlights three proven strategies—early master‑plan development, continuous quality improvement, and data‑driven analytics—to...
Roche’s oral breast‑cancer therapy, touted as a potential blockbuster, missed its primary endpoint in the pivotal Phase 3 persevERA trial. The study evaluated the drug as a first‑line treatment for hormone‑receptor‑positive, HER2‑negative metastatic breast cancer and enrolled more than 1,200 patients...
Kyron.bio announced a strategic partnership with Servier to glycoengineer a Servier‑selected antibody using its precision glycosylation platform. Servier will fund the research and retain an option to pursue further development based on the results. The collaboration builds on Kyron.bio’s 2024...
Under the Trump administration, the U.S. government slashed nearly $500 million in mRNA research funding, canceling 22 projects and a $766 million Moderna contract. The FDA’s initial refusal then reversal to review Moderna’s flu vaccine highlighted regulatory skepticism toward the platform. Private‑sector...
Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance "findings suggest that mitochondrial quality control is a key determinant of resistance to ABT263-induced and ARV825-induced senolysis, providing a possible framework for rational combination senotherapies." https://t.co/xB0wFkzIW9
The article presents a step‑by‑step Python tutorial that builds a full single‑cell RNA‑sequencing (scRNA‑seq) analysis pipeline using Scanpy. It walks through data loading, quality‑control filtering, normalization, highly variable gene selection, PCA, neighbor‑graph construction, UMAP embedding, Leiden clustering, and marker‑gene based...
Editas Medicine reported Q2 2024 progress on its gene‑edited cell therapy reni‑cel, presenting interim data from the RUBY sickle‑cell and EdiTHAL beta‑thalassemia trials. All 18 RUBY patients were free of vaso‑occlusive events, with hemoglobin levels above 14 g/dL and fetal hemoglobin exceeding...
